Dr. Jonathan D. Leffert, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 695
Licensed in Texas since 1984, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TX license G7081 (first issued 1984; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Texas Health Presbyterian Hospital Dallas Dallas, TX
Medical groups
- North Texas Endocrine Center, P.a. (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 695
- Services billed
- 3,384
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 918 | 420 |
| Blood glucose (sugar) test performed by hand-held instrument | 759 | 265 |
| Hemoglobin a1c level | 564 | 249 |
| Established patient office or other outpatient visit, 20-29 minutes | 422 | 318 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 341 | 123 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 230 | 47 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 149 | 40 |
| Ultrasound scan of head and neck soft tissue | 98 | 91 |
| New patient office or other outpatient visit, 45-59 minutes | 95 | 95 |
| New patient office or other outpatient visit, 30-44 minutes | 70 | 70 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Dallas, TX | 397 |
| Synthroid (levothyroxine sodium) Other prescribers in Dallas, TX | 322 |
| Ozempic (semaglutide) Other prescribers in Dallas, TX | 207 |
| Alendronate Sodium Other prescribers in Dallas, TX | 182 |
| Metformin Hcl Other prescribers in Dallas, TX | 174 |
| Jardiance (empagliflozin) Other prescribers in Dallas, TX | 109 |
| Mounjaro (tirzepatide) Other prescribers in Dallas, TX | 78 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Dallas, TX | 71 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Dallas, TX | 67 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Dallas, TX | 64 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 39 payments worth $1,159 in total to this clinician.
| Chiesi USA, Inc. | $300 |
|---|---|
| Tandem Diabetes Care, Inc. | $92.37 |
| Lilly USA, LLC | $85.72 |
| Novo Nordisk Inc | $68.53 |
| Cequr Corporation | $59.16 |
| Sanofi-aventis U.S. LLC | $58.98 |
| Abbott Laboratories | $56.44 |
| Radius Health, Inc. | $47.67 |
| Food and Beverage | $835 |
|---|---|
| Honoraria | $300 |
| Education | $24.04 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Feb 4, 2025 | Honoraria MYCAPSSA · ACROMEGALY | $300 |
| Neurocrine Biosciences, Inc. Apr 2, 2025 | Education CRENESSITY · Neuropsychiatry · in-kind | $24.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.